Literature DB >> 22688762

Isolation of recombinant MVA using F13L selection.

Juana M Sánchez-Puig1, María M Lorenzo, Rafael Blasco.   

Abstract

Modified vaccinia virus Ankara (MVA) has become a widely used vector for vaccine and laboratory purposes. Despite significant advances in recombinant MVA technology, the isolation of recombinant viruses remains a tedious and difficult process. This chapter describes the use of an efficient and easy-to-use selection system adapted for MVA. The system is based on the requirement of the viral gene F13L for efficient virus spread in cell culture, which results in a severe block in virus transmission when F13L gene is deleted (Blasco R, Moss B. J Virol 65:5910-5920, 1991; Blasco R, Moss B. J Virol 66:4170-4179, 1992). The insertion of foreign genes in the MVA genome is accomplished by recombination of a transfected plasmid carrying the foreign genes and the F13L with the genome of an F13L knockout virus. Subsequently, selection of virus recombinants is carried out by serial passage and/or plaque purification of viruses that have recovered the F13L gene.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688762     DOI: 10.1007/978-1-61779-876-4_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  A protective bivalent vaccine against Rift Valley fever and bluetongue.

Authors:  Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Julio Benavides; Aitor Nogales; Rafael Blasco; Alejandro Brun; Javier Ortego
Journal:  NPJ Vaccines       Date:  2020-07-30       Impact factor: 7.344

2.  Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Authors:  Felicia Roscoe; Ren-Huan Xu; Luis J Sigal
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

3.  A vaccinia virus recombinant transcribing an alphavirus replicon and expressing alphavirus structural proteins leads to packaging of alphavirus infectious single cycle particles.

Authors:  Juana M Sánchez-Puig; María M Lorenzo; Rafael Blasco
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

4.  Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.

Authors:  María M Lorenzo; Aitor Nogales; Kevin Chiem; Rafael Blasco; Luis Martínez-Sobrido
Journal:  Microbiol Spectr       Date:  2022-05-18

5.  Vaccinia virus and Cowpox virus are not susceptible to the interferon-induced antiviral protein MxA.

Authors:  María M Lorenzo; Juana M Sanchez-Puig; Rafael Blasco
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

6.  A protective bivalent vaccine against Rift Valley fever and bluetongue.

Authors:  Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Julio Benavides; Aitor Nogales; Rafael Blasco; Alejandro Brun; Javier Ortego
Journal:  NPJ Vaccines       Date:  2020-07-30       Impact factor: 7.344

7.  Comparison of Recombinant MVA Selection Methods Based on F13L, D4R and K1L Genes.

Authors:  Irina V Antoshkina; Dina V Glazkova; Felix A Urusov; Elena V Bogoslovskaya; German A Shipulin
Journal:  Viruses       Date:  2022-03-04       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.